The The Relationship Between Serum miRNAs and Surgical Prognostic Factors in Gastric Cancers

Serum MiRNAs in Gastric Cancer Surgery

Abstract

There is a continued need for biomarkers in patients with gastric cancer that can aid in diagnosis, treatment follow-up, and relapse detection. The objective of this study is to investigate the role of serum miRNAs in diagnosing gastric cancer and their relationship with prognostic factors that impact the choice of surgical approach.

We compared the serum miRNA expression levels of 35 patients who underwent gastrectomy and D2 lymph node dissection for gastric adenocarcinoma between 2015-2018 with those of 33 controls. We also evaluated the relationship between serum miRNA expression levels and pathological prognostic factors.

Serum levels of miR-17-5p, miR-21-5p, miR-27a-3p, miR-146a-5p, miR-148a-3p, and miR-203a-3p were significantly higher in gastric cancer patients. In early gastric cancer patients, serum levels of miR-21-5p, miR-27a-3p, miR-106b-5p, miR-146a-5p, and miR-148a-3p were significantly higher. Furthermore, serum levels of miR-106b-5p and miR-146a-5p were associated with tumor localization (AUC: 0.773, 0.797; p: 0.049, 0.036), while serum levels of miR-27a-3p and miR-148a-5p were associated with the T stage of the tumor (AUC: 0.748, 0.729; p: 0.036, 0.049).

Serum levels of miR-17-5p, miR-21-5p, miR-27a-3p, and miR-203a-3p were found to be diagnostic biomarkers in gastric cancers. The expression levels of serum miR-106b-5p and miR-146a-5p were found to be related to tumor location, while the expression levels of serum miR-27a-3p and miR-148a-5p were found to be related to the T stage of the tumor. These findings can impact the surgical approach for gastric cancer patients.